

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated monoclonal antibody, or an antigen-binding antibody fragment, that binds to the amino acid sequence from residues 14-452 of SEQ ID NO:1, wherein the antibody preferentially binds cell-associated CA 125/O772P polypeptide relative to shed CA 125/O772P polypeptide.

2. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 1, wherein the antibody or antibody fragment, in an ELISA Competition Assay, exhibits less than ~~about~~ 25% inhibition of binding to the peptide of SEQ ID NO:1 in the presence of a 25-fold (weight/weight) excess of shed CA 125/O772P over the peptide of SEQ ID NO:1.

3. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 2, wherein the antibody or antibody fragment, in an ELISA Competition Assay, exhibits less than ~~about~~ 20% inhibition of binding to the peptide of SEQ ID NO:1 in the presence of a 25-fold (weight/weight) excess of shed CA 125/O772P over the peptide of SEQ ID NO:1.

4. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 3, wherein the antibody or antibody fragment, in an ELISA Competition Assay, exhibits less than ~~about~~ 15% inhibition of binding to the peptide of SEQ ID NO:1 in the presence of a 25-fold (weight/weight) excess of shed CA 125/O772P over the peptide of SEQ ID NO:1.

5. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 4, wherein the antibody or antibody fragment, in an ELISA Competition Assay, exhibits less than ~~about~~ 10% inhibition of binding to the peptide of SEQ ID NO:1 in the presence of a 25-fold (weight/weight) excess of shed CA 125/O772P over the peptide of SEQ ID NO:1.

6. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 5, wherein the antibody or antibody fragment, in an ELISA Competition Assay, exhibits less than ~~about~~ 5% inhibition of binding to the peptide of SEQ ID NO:1 in the presence of a 25-fold (weight/weight) excess of shed CA 125/O772P over the peptide of SEQ ID NO:1.

7. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 1, wherein the antibody or antibody fragment, in a Flow Cytometry Assay, exhibits an IC₅₀, as measured by percent-positive cells, of at least ~~about~~ 0.05 mg/ml shed CA 125/O772P.

8. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 7, wherein the antibody or antibody fragment, in a Flow Cytometry Assay, exhibits an IC₅₀, as measured by percent-positive cells, of at least ~~about~~ 0.25 mg/ml shed CA 125/O772P.

9. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 8 wherein the antibody or antibody fragment, in a Flow Cytometry Assay, exhibits an IC₅₀, as measured by percent-positive cells, of at least ~~about~~ 0.5 mg/ml shed CA 125/O772P.

10. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 9, wherein the antibody or antibody fragment, in a Flow Cytometry Assay, exhibits an IC₅₀, as measured by percent-positive cells, of at least ~~about~~ 0.75 mg/ml shed CA 125/O772P.

11. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 10, wherein the antibody or antibody fragment, in a Flow Cytometry Assay, exhibits an IC₅₀, as measured by percent-positive cells, of at least ~~about~~ 1.0 mg/ml shed CA 125/O772P.

12. (Previously Presented) The isolated antibody, or the antigen-binding antibody fragment, of Claim 1, wherein the antibody or antibody fragment binds the peptide of SEQ ID NO:1, but does not detectably bind shed CA 125/O772P.

13. (Original) The isolated antibody of Claim 1, wherein the antibody is an IgG class antibody.
14. (Original) The isolated antibody of Claim 13, wherein the antibody is an IgG₁ isotype.
15. (Original) The isolated antibody of Claim 1, wherein the antibody is a monoclonal antibody.
16. (Original) The isolated antibody of Claim 15, wherein the antibody is a chimeric monoclonal antibody.
17. (Original) The isolated antibody of Claim 16, wherein the chimeric monoclonal antibody comprises a C γ 1 constant region.
18. (Original) The isolated antibody of Claim 16, wherein the chimeric monoclonal antibody comprises a C γ 4 constant region.
19. (Original) The isolated antibody of Claim 1, wherein the antibody is a humanized monoclonal antibody.
20. (Original) The isolated antibody of Claim 15, wherein the antibody is a human monoclonal antibody.
21. (Original) The isolated antibody of Claim 1, wherein the antibody is a bi-specific antibody.
22. (Original) The isolated antibody of Claim 1, wherein the antibody is a multi-specific antibody.
23. (Original) The isolated antibody of Claim 1, wherein the antibody is a chimeric antibody.
24. (Original) The isolated antibody of Claim 1, wherein the antibody is a single chain antibody, a disulfide-linked F_{vs}, a single chain F_{vs}, or an anti-idiotypic antibody.
25. (Canceled)

26. (Original) A monoclonal antibody produced by hybridoma 4E7 (ATCC® Accession No. PTA-5109), 7A11 (ATCC® Accession No. PTA-5110), 7C6 (ATCC® Accession No. PTA-5111), 7F10 (ATCC® Accession No. PTA-5112), 7G10 (ATCC® Accession No. PTA-5245), 7H1 (ATCC® Accession No. PTA-5114), 8A1 (ATCC® Accession No. PTA-5115), 8B5 (ATCC® Accession No. PTA-5116), 8C3 (ATCC® Accession No. PTA-5246), 8E3 (ATCC® Accession No. PTA-5118), 8G9 (ATCC® Accession No. PTA-5119), 15C9 (ATCC® Accession No. PTA-5106), 16C7 (ATCC® Accession No. PTA-5107), 16H9 (ATCC® Accession No. PTA-5108), 117.1 (ATCC® Accession No. PTA-4567), 325.1 (ATCC® Accession No. PTA-5120), 368.1 (ATCC® Accession No. PTA-4568), 446.1 (ATCC® Accession No. PTA-5549), 501.1 (ATCC® Accession No. PTA-4569), 621.1 (ATCC® Accession No. PTA-5121), 633.1 (ATCC® Accession No. PTA-5122), 654.1 (ATCC® Accession No. PTA-5247), 725.1 (ATCC® Accession No. PTA-5124), or 776.1 (ATCC® Accession No. PTA-4570).

27. (Original) A monoclonal antibody that competes with binding of the monoclonal antibody of Claim 26.

28. (Original) A hybridoma as deposited as hybridoma 4E7 (ATCC® Accession No. PTA-5109), 7A11 (ATCC® Accession No. PTA-5110), 7C6 (ATCC® Accession No. PTA-5111), 7F10 (ATCC® Accession No. PTA-5112), 7G10 (ATCC® Accession No. PTA-5245), 7H1 (ATCC® Accession No. PTA-5114), 8A1 (ATCC® Accession No. PTA-5115), 8B5 (ATCC® Accession No. PTA-5116), 8C3 (ATCC® Accession No. PTA-5246), 8E3 (ATCC® Accession No. PTA-5118), 8G9 (ATCC® Accession No. PTA-5119), 15C9 (ATCC® Accession No. PTA-5106), 16C7 (ATCC® Accession No. PTA-5107), 16H9 (ATCC® Accession No. PTA-5108), 117.1 (ATCC® Accession No. PTA-4567), 325.1 (ATCC® Accession No. PTA-5120), 368.1 (ATCC® Accession No. PTA-4568), 446.1 (ATCC® Accession No. PTA-5549), 501.1 (ATCC® Accession No. PTA-4569), 621.1 (ATCC® Accession No. PTA-5121), 633.1 (ATCC® Accession No. PTA-5122), 654.1 (ATCC® Accession No. PTA-5247), 725.1 (ATCC® Accession No. PTA-5124), or 776.1 (ATCC® Accession No. PTA-4570).

29. - 43. (Canceled)

44. (Previously Presented) The isolated antibody, or antigen-binding antibody fragment, of Claim 1, wherein the antibody or antigen-binding antibody fragment comprises a light chain variable region that comprises the amino acid sequence depicted in SEQ ID NO:33,

and wherein the antibody or antigen-binding antibody fragment comprises a heavy chain variable region that comprises the amino acid sequence depicted in SEQ ID NO:34.

45. - 48. (Canceled)

49. (Currently Amended) The isolated antibody, or antigen-binding antibody fragment, of Claim 1, wherein the antibody, or antigen-binding antibody fragment binds the peptide of SEQ ID NO:1 with a K_d of less than ~~about~~ 100nM as measured in an antigen-antibody affinity assay.

50. (Currently Amended) The isolated antibody, or antigen-binding antibody fragment, of Claim 49, wherein the antibody, or antigen-binding antibody fragment binds the peptide of SEQ ID NO:1 with a K_d of less than ~~about~~ 10nM as measured in an antigen-antibody affinity assay.

51. (Currently Amended) The isolated antibody, or antigen-binding antibody fragment, of Claim 50, wherein the antibody, or antigen-binding antibody fragment binds the peptide of SEQ ID NO:1 with a K_d of less than ~~about~~ 1nM as measured in an antigen-antibody affinity assay.

52. (Currently Amended) The isolated antibody, or antigen-binding antibody fragment, of Claim 51, wherein the antibody, or antigen-binding antibody fragment binds the peptide of SEQ ID NO:1 with a K_d of less than ~~about~~ 100pM as measured in an antigen-antibody affinity assay.

53. (Currently Amended) The isolated antibody, or antigen-binding antibody fragment, of Claim 52, wherein the antibody, or antigen-binding antibody fragment binds the peptide of SEQ ID NO:1 with a K_d of less than ~~about~~ 10pM as measured in an antigen-antibody affinity assay.

54.-55. (Canceled)

56. (Previously Presented) The isolated antibody, or the antigen-binding antibody fragment, of Claim 1, wherein the antibody or antibody fragment mediates lysis of a CA 125/O772P-positive tumor cell in an antibody-dependent cellular cytotoxicity (“ADCC”) assay.

57. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 56, wherein the antibody or antibody fragment mediates at least about 10% lysis of α -CA 125/O772P-positive tumor cells in an ADCC assay at a 50:1 effector:target ratio at a concentration of 5.0 μ g antibody or antigen-binding fragment per ml.

58. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 56, wherein the antibody or antibody fragment mediates at least about 10% lysis of α -CA 125/O772P-positive tumor cells in an ADCC assay at a 25:1 effector:target ratio at a concentration of 5.0 μ g antibody or antigen-binding fragment per ml.

59. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 56, wherein the antibody or antibody fragment mediates at least about 10% lysis of α -CA 125/O772P-positive tumor cells in an ADCC assay at a 12.5:1 effector:target ratio at a concentration of 5.0 μ g antibody or antigen-binding fragment per ml.

60. (Currently Amended) The isolated antibody, or the antigen-binding antibody fragment, of Claim 56, wherein the antibody or antibody fragment mediates at least about 10% lysis of a CA 125/O772P-positive tumor cell in an ADCC assay at a 12.5:1 effector:target ratio at a concentration of 50 ng antibody or antigen-binding fragment per ml.

61. (Original) The isolated antibody, or the antigen-binding antibody fragment, of Claim 1, wherein the antibody or antibody fragment mediates lysis of a CA 125/O772P-positive tumor cell in an complement-dependent cytotoxicity (CDC) assay.

62. (Original) The isolated antibody, or the antigen-binding antibody fragment, of Claim 61, wherein the antibody or antibody fragment mediates in a range from about 15% lysis at 5 μ g/ml antibody or antigen-binding antibody fragment to about 95% lysis at about 0.1 μ g/ml antibody or antigen-binding antibody fragment.

63. – 76. (Canceled)

77. (Currently Amended) A fusion polypeptide comprising an antibody, or an antigen-binding antibody fragment, which preferentially binds cell-associated CA 125/O772P relative to shed CA 125/O772P, wherein the isolated antibody, or the antigen-binding antibody

| fragment, binds to the amino acid sequence from residues 14-452 of SEQ ID NO:1, operably linked to a heterologous agent.

78. - 102. (Canceled)

103. (Original) A hybridoma that can secrete an antibody of Claim 1.

104. (Original) The isolated antibody or antigen-binding fragment of Claim 1 conjugated to a cytotoxic agent.

105. (Original) The isolated antibody or antigen-binding fragment of Claim 104, wherein the cytotoxic agent is a radioisotope.

106. (Original) The isolated antibody or antigen-binding fragment of Claim 105, wherein the radioisotope is selected from the group consisting of ^{125}I , ^{131}I , ^{111}In , $^{99\text{m}}\text{Tc}$ and ^{90}Y .

107. (Original) The monoclonal antibody of Claim 26 or 27, which is conjugated to a cytotoxic agent.

108. (Original) The monoclonal antibody of Claim 107, wherein the cytotoxic agent is a radioisotope.

109. (Original) The monoclonal antibody of Claim 108, wherein the radioisotope is selected from the group consisting of ^{125}I , ^{131}I , ^{111}In , $^{99\text{m}}\text{Tc}$ and ^{90}Y .

110. – 115. (Canceled)

116. (Original) A monoclonal antibody selected from the group consisting of 325.1, 621.1, 633.1, 654.1, 725.1, 8G9, 7F10, 8A1, 8C3, 15C9, 8E3, 8B5, 7G10, 16C7, 7C6, 7H1, 16H9, 7A11, 4E7, 117.1, 368.1, 446.1, 501.1, and 776.1, or an antigen-binding antibody fragment thereof.

117. (Previously Presented) An isolated antibody or antigen-binding antibody fragment that competes with binding of a monoclonal antibody of Claim 116.

118. – 119. (Canceled)